SVB Leerink Upgrades Pacira Pharmaceuticals (PCRX) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Price: $36.35 --0%
Rating Summary:
9 Buy, 19 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 10 | New: 15
Rating Summary:
9 Buy, 19 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 10 | New: 15
Join SI Premium – FREE
SVB Leerink analyst Ami Fadia upgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Market Perform to Outperform with a price target of $44.00 (from $46.00).
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $32.52 yesterday.
You May Also Be Interested In
- JPMorgan Upgrades Rumo SA (RAIL3:BZ) to Overweight
- Barclays Upgrades Viking Holdings (VIK) to Overweight
- Sega Sammy Holdings Inc. (6460:JP) (SGAMY) PT Raised to JPY3,700 at Citi
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
